Acadian Asset Management LLC Cyma Bay Therapeutics, Inc. Transaction History

Acadian Asset Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	BUY	$1.72 - $3.39 $54,742 - $107,893	31,827 New	31,827 $94,000
Q2 2020 Aug 12, 2020	SELL	$1.41 - $4.25 $861,928 - $2.6 Million	-611,297 Closed	0 $0
Q1 2020 May 11, 2020	BUY	$1.25 - $2.02 $247,502 - $399,964	198,002 Added 47.91%	611,297 $906,000
Q4 2019 Feb 06, 2020	BUY	$1.33 - $5.93 $549,682 - $2.45 Million	413,295 New	413,295 $810,000
Q2 2018 Jul 24, 2018	SELL	$10.66 - $14.38 $360,329 - $486,072	-33,802 Closed	0 $0
Q1 2018 Apr 12, 2018	BUY	$9.0 - $15.16 $304,218 - $512,438	33,802 New	33,802 $439,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.